PHASE I/II STUDY OF ERLOTINIB AND TEMSIROLIMUS (CCI-779) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)

被引：0

作者：

Wen, Patrick ^{[1
]}

Kuhn, John ^{[2
]}

Chang, Susan ^{[3
]}

Lamborn, Kathleen ^{[3
]}

Robbins, Hi ^{[4
]}

Cloughesy, Timothy ^{[5
]}

Lieberman, Frank ^{[6
]}

Mehra, Minesh ^{[7
]}

Gilbert, Mark

Cooper, Josh

Drappatz, Jan ^{[8
]}

Kesari, Santosh

Norden, Andrew

Groves, Morris ^{[9
]}

Aldape, Kenneth ^{[9
]}

Yung, W. K. Alfred ^{[9
]}

Dancey, Janet ^{[10
]}

Prados, Michael ^{[3
]}

机构：

[1] Ctr Neurooncol, Boston, MA USA

[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Univ Wisconsin, Madison, WI 53706 USA

[5] Univ Calif Los Angeles, Los Angeles, CA USA

[6] Univ Pittsburgh, Pittsburgh, PA USA

[7] Univ Wisconsin, Madison, WI USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] NCI, Bethesda, MD 20892 USA

来源：

NEURO-ONCOLOGY | 2008年 / 10卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：824 / 824

页数：1

共 50 条

[31] A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: AChildren's Oncology Group Phase I Consortium Report
Fouladi, Maryam
Perentesis, John P.
Wagner, Lars M.
Vinks, Alexander A.
Reid, Joel M.
Ahern, Charlotte
Thomas, George
Mercer, Carol A.
Krueger, Darcy A.
Houghton, Peter J.
Doyle, L. Austin
Chen, Helen
Weigel, Brenda
Blaney, Susan M.
CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1558 - 1565
[32] Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
Witzig, T
Geyer, S
Ghobrial, I
Inwards, D
Fonseca, R
Kurtin, P
Ansell, S
Kaufmann, S
ANNALS OF ONCOLOGY, 2005, 16 : 65 - 65
[33] FEASIBILITY/TOLERABILITY RESULTS FROM A PHASE I/II STUDY OF TEMSIROLIMUS (CCI-779) AND SORAFENIB IN RECURRENT GLIOBLASTOMA: NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) N0572
Schiff, David
Sarkaria, Jann
Decker, Paul
Buckner, Jan
Galanis, Evanthia
Dancey, Janet
Giannini, Caterina
Brown, Paul
Wiesenfeld, Martin
Jaeckle, Kurt
NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
[34] Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas
Sathornsumetee, S.
Desjardins, A.
Vredenburgh, J. J.
Rich, J. N.
Gururangan, S.
Friedman, A. H.
Friedman, H. S.
Reardon, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[35] Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08)
Wen, PY
Yung, WKA
Lamborn, K
Peng, B
Dahia, P
Abrey, L
Raiser, J
Cloughesy, T
Fink, K
Gilbert, M
Chang, S
Junck, L
Schiff, D
Lieberman, F
Fine, H
Mehta, M
Robins, HI
DeAngelis, LM
Hess, K
Groves, M
Puduvalli, VK
Levin, V
Conrad, C
Kuhn, J
Maher, E
Hayes, M
Silberman, S
Letvak, L
Capdeville, R
Kaplan, R
Murgo, A
Stiles, C
Prados, MD
NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
[36] A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas A Study of the Mayo Phase 2 Consortium (P2C)
Okuno, Scott
Bailey, Howard
Mahoney, Michelle R.
Adkins, Douglas
Maples, William
Fitch, Tom
Ettinger, David
Erlichman, Charles
Sarkaria, Jann N.
CANCER, 2011, 117 (15) : 3468 - 3475
[37] Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Ghobrial, Irene M.
Weller, Edie
Vij, Ravi
Munshi, Nikhil C.
Banwait, Ranjit
Rourke, Meghan
Schlossman, Robert L.
Laubach, Jacob P.
Jakubowiak, Andrzej J.
Leduc, Renee
Chuma, Stacey
Kunsman, Janet
Dollard, Akari M.
Warren, Diane
Harris, Brianna
Poon, Tiffany
Sam, Amy
Rodig, Scott J.
Anderson, Kenneth C.
Richardson, Paul G.
BLOOD, 2010, 116 (21) : 435 - 436
[38] Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
Sarantopoulos, J.
Lenz, H.
LoRusso, P.
Shibata, S.
Kummar, S.
Mulkerin, D.
Ramanathan, R. K.
Mita, M. M.
O'Rourke, P.
Remick, S. C.
Goel, S.
Gutierrez, M.
Ramalingam, S. S.
Murgo, A.
Davies, A. M.
Mani, S.
Boni, J.
Shapiro, M.
Ivy, S. P.
Takimoto, C. H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[39] A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor.
Hidalgo, M
Rowinsky, E
Erlichman, C
Drengler, R
Marshall, B
Marks, R
Edwards, T
Boni, J
Dukart, G
Buckner, J
ANNALS OF ONCOLOGY, 2000, 11 : 133 - 133
[40] Phase I/II study of vandetanib for patients with recurrent malignant gliomas.
Mcnicol, K. A.
Kreisl, T. N.
Iwamoto, F. M.
Sul, J.
Fine, H. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →